The aim of this review is to analyse critically the recent literature on the clinical
pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplant recipients …

Annually, about 8000 heart and lung transplantations are successfully performed worldwide.
However, morbidity and mortality still pose a major concern. Renal failure in heart and lung …

Despite a lower content of many drug metabolising enzymes in the intestinal epithelium
compared to the liver (eg intestinal CYP3A abundance in the intestine is 1% that of the liver) …

The calcineurin inhibitors (CNIs) tacrolimus and cyclosporine are widely used
immunosuppressive drugs characterized by high pharmacokinetic and pharmacodynamic …

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Patients with low tacrolimus troughs
are at a higher risk of rejection while those with high troughs are at an increased risk for …

Calcineurin inhibitors, tacrolimus (FK506) and cyclosporine (ciclosporin A), are the primary
immunosuppressive agents used on recipients of organ transplantations. The hepatic …

Background. The CYP4503A5* 1 genotype is associated with lower tacrolimus
concentrations. Although its effect is important, it incompletely explains the variability in …

The aim of this study was to develop a population pharmacokinetic model of tacrolimus in
pediatric kidney transplant patients, identify factors that explain variability, and determine …

The application of machine learning (ML) has shown promising results in precision medicine
due to its exceptional performance in dealing with complex multidimensional data. However …

Aim Several tacrolimus population pharmacokinetic models in adult renal transplant
recipients have been established to facilitate dose individualization. However, their …